Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,190.00
Bid: 12,210.00
Ask: 12,214.00
Change: 162.00 (1.35%)
Spread: 4.00 (0.033%)
Open: 12,036.00
High: 12,214.00
Low: 12,024.00
Prev. Close: 12,028.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-EU to extend vaccine export curbs to cover Britain, backloading -source

Tue, 23rd Mar 2021 16:31

* EU Commission to propose tighter mechanism on Weds

* Even firms meeting quarterly supply contracts may be hit

* Export block to also hit states with higher shot rates

* J&J has signalled backloaded Q2 deliveries to EU
(Adds Prime Minister Boris Johnson)

By Francesco Guarascio

BRUSSELS, March 23 (Reuters) - The European Commission will
on Wednesday extend EU powers to potentially block COVID-19
vaccine exports to Britain and other areas with much higher
vaccination rates, and to cover instances of companies
backloading contracted supplies, an EU official said.

The moves, which the EU official said could hit Johnson &
Johnson, are designed to avoid even limited shortfalls
in deliveries to a region whose inoculation programme has been
beset by delays and supply issues.

Shipments abroad could also be withheld if vaccine-producing
countries, such as Britain and the United States, do not allow
exports to the EU, the official said, confirming comments by
Commission head Ursula von der Leyen last week.

As tensions between London and Brussels rose on Monday over
a possible export ban, Britain demanded that EU authorities
allow the delivery of COVID-19 vaccines it has ordered.

On Tuesday, Prime Minister Boris Johnson said Britain did
not believe in imposing vaccine blockades. "I'm encouraged by
some of the things I've heard from the continent in the same
sense," he told a news briefing.

Johnson & Johnson has announced delays in its supplies to
the EU in the second quarter, which the EU official said could
lead to consequences under the Commission amendment covering
companies backloading contracted quarterly deliveries.

All vaccine makers could potentially be affected, added the
official, who has direct knowledge of the Commission decision.

'WE DON'T WANT THE SAME DELAYS IN Q2'

The EU this month used an existing export control mechanism,
set up at the end of January, to block a shipment of AstraZeneca
vaccine to Australia.

That mechanism can at present be activated only if companies
do not meet contracted quarterly delivery targets. The
AstraZeneca exports were blocked after the company announced
steep cuts in first quarter deliveries to the EU.

With the amendments to be adopted on Wednesday, the EU will
however be able to block exports to cover companies that respect
their quarterly contracts but backload supplies to the end of
the period, said the official, who asked to remain anonymous.

Johnson & Johnson, which has committed to delivering 55
million doses to the EU between April and June, has said its
deliveries were likely to start in the second half of April
.

The company told EU officials it was facing production
issues that might make it difficult to meet its second quarter
target, but that was striving to fulfil it..

Moderna and Pfizer/BioNTech also
had delays in their vaccine delivery rollouts to the EU, though
they are set to meet their overall targets for the first
quarter.

"We don't want the same delays to happen in the second
quarter," said the official.

Any decision to bloc an export would however need to be
taken in agreement with the EU state from where the shipment
would leave the bloc, and take into account the overall stance
of a company and of the importing state. "We will balance things
out," the official said.

The new rules, which will take effect immediately after
publication in the EU official journal, will also tighten
controls to make sure export blocks are not circumvented using
third countries, the official said.

The U.S. administration told EU officials in March that it
would not allow any time soon the shipment to the EU of
AstraZeneca vaccines produced in the United States, EU officials
told Reuters.

(Reporting by Francesco Guarascio @fraguarascio; editing by
John Stonestreet)

More News
30 May 2024 09:23

LONDON BROKER RATINGS: Jefferies and UBS cut Anglo American

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:

Read more
30 May 2024 07:40

LONDON BRIEFING: Dr Martens cuts payout as profit plummets

(Alliance News) - Stocks in London are called to open lower on Thursday, with investors nervous ahead of Friday's US inflation print.

Read more
29 May 2024 08:54

IN BRIEF: AstraZeneca drug lowers cholesterol in phase 1 trial

AstraZeneca PLC - Cambridge, England-based pharmaceuticals - Reports positive results in a phase 1 trial of cholesterol drug candidate AZD0780, an oral small molecule PCSK9 inhibitor. Administered on top of rosuvastatin treatment, AZD0780 showed a statistically significant reduction in low-density lipoprotein cholesterol in plasma for test participants with hypercholesterolaemia, Astra says, while no serious adverse events were reported. "Elevated LDL-C levels in plasma is a key risk factor for cardiovascular disease and is estimated to cause 2.6 million deaths worldwide annually," Astra notes.

Read more
28 May 2024 07:02

AstraZeneca experimental lung cancer drug shows promising results

(Sharecast News) - AstraZeneca's experimental lung cancer drug showed improved overall survival rates in phase III trials, the pharmaceutical giant said on Tuesday.

Read more
27 May 2024 07:49

IN BRIEF: Astra, Daiichi hail positive survival data for Dato-DXd

AstraZeneca PLC - Cambridge, UK-based pharmaceutical firm - Alongside Japan's Daiichi Sankyo Co Ltd, notes positive data for datopotamab deruxtecan in phase III trial on lung cancer. Says the treatment, also known as Dato-DXd, showed a clinically meaningfully improvement in overall survival versus chemotherapy in advanced nonsquamous non-small cell lung cancer. The results build upon the positive progression-free survival findings presented back in 2023, Astra adds.

Read more
22 May 2024 09:53

LONDON BROKER RATINGS: Barclays cuts NextEnergy but lifts JLEN

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
22 May 2024 02:00

British firms expecting hard time in China market, lobby group warns

BEIJING, May 22 (Reuters) - British firms expect doing business in China to become harder over the next five years, a British business lobby group said on Wednesday, as Beijing strives to halt a retreat in foreign funds from a market once seen as the engine of global growth.

Read more
21 May 2024 19:00

Sector movers: Stocks slip amid light profit-taking

(Sharecast News) - Stocks ended a tad lower as investors waited on a raft of US central bank speakers scheduled for after the close of markets in London.

Read more
21 May 2024 17:20

Europe's STOXX 600 ends lower as rate uncertainty prevails

Focus on Fed minutes, Nvidia earnings

*

Read more
21 May 2024 17:04

LONDON MARKET CLOSE: London dips as eyes turn to UK inflation reading

(Alliance News) - Stock prices in London closed in the red on Tuesday, as investors nervously eye a key UK inflation reading, which could prompt the Bank of England to consider interest rate cuts.

Read more
21 May 2024 15:00

London close: Stocks fall ahead of key inflation reading

(Sharecast News) - London stocks ended in negative territory on Tuesday, influenced by the latest UK economic outlook from the International Monetary Fund (IMF) and comments from US Federal Reserve officials.

Read more
21 May 2024 12:03

CORRECT: Stocks fall but pound up as IMF ups UK forecast

(Correcting London Stock Exchange index prices.)

Read more
21 May 2024 12:00

LONDON MARKET MIDDAY: Stocks fall but pound up as IMF ups UK forecast

(Alliance News) - Stock prices in Europe were lower heading into Tuesday afternoon, with shares in New York also set for a muted open, as a recent rally for equities takes a pause.

Read more
21 May 2024 11:23

AstraZeneca aims for $80 bln in total revenue by 2030

Sees $80 bln in 2030 revenue by 2030

*

Read more
21 May 2024 09:04

LONDON MARKET OPEN: FTSE 100 declines after Asian stocks fall

(Alliance News) - Stock prices in London opened in the red on Tuesday, with some US interest rate cut optimism cooling after hawkish words from Federal Reserve central bankers.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.